The start of Galapagos NV’s phase IIa trial with its cystic fibrosis (CF) therapy, GLPG1832, triggered new speculation regarding what’s ahead for the apparently solid franchise in the space held by Vertex Pharmaceuticals Inc., a company that Morningstar analyst Stefan Quenneville called “a rare gem,” with CF drugs on the market and in the pipeline that are still not given their due on Wall Street.